[go: up one dir, main page]

WO2008101935A3 - Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant - Google Patents

Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
WO2008101935A3
WO2008101935A3 PCT/EP2008/052025 EP2008052025W WO2008101935A3 WO 2008101935 A3 WO2008101935 A3 WO 2008101935A3 EP 2008052025 W EP2008052025 W EP 2008052025W WO 2008101935 A3 WO2008101935 A3 WO 2008101935A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
group
alkyl
hydrogen atom
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/052025
Other languages
English (en)
Other versions
WO2008101935A2 (fr
Inventor
Fabrice Lejeune
Jamal Tazi
David Grierson
Christian Rivalle
Florence Mahuteau-Betzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2677877A priority Critical patent/CA2677877C/fr
Priority to JP2009549836A priority patent/JP5544170B2/ja
Priority to US12/527,071 priority patent/US8895726B2/en
Priority to ES08716957.9T priority patent/ES2569478T3/es
Priority to CN2008800053707A priority patent/CN101652364B/zh
Priority to EP08716957.9A priority patent/EP2121685B1/fr
Publication of WO2008101935A2 publication Critical patent/WO2008101935A2/fr
Publication of WO2008101935A3 publication Critical patent/WO2008101935A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé dérivé d'indole correspondant à la formule (II) dans laquelle X représente N, CR8 ou N+ R8, où R8 représente un atome d'hydrogène, un groupement hydroxyle ou alkyle ou méthoxy éventuellement substitué par un groupement phényle; R2, R3 et R4 représentent indépendamment un atome d'hydrogène ou un atome d'halogène ou un groupement alkyle, amine, alcène, ester, sulfonamide, éther ou benzyle, éventuellement substitués; R5 représente un atome d'hydrogène ou un groupement alkyle, amine, benzyle éventuellement substitués; R6 représente un groupement alkyle en C1-C3 éventuellement substitué; R7 représente un atome d'hydrogène ou un groupement alkyle en C1-C3 éventuellement substitué et R7 est absent lorsque le cycle A est en position b, et A représente un cycle; R9 et R10 représentent ensemble une liaison carbone ou représentent indépendamment un groupement R11, OR11, SR11; où R11 représente un hydrogène, un groupement alkyle en C1-C3 saturé ou insaturé, éventuellement substitué, pouvant contenir un ou plusieurs atomes de soufre, d'oxygène ou d'azote; les sels pharmaceutiquement acceptables desdits composés, leurs isomères et/ou mélange de ceux-ci; une composition pharmaceutique comprenant un tel composé; et l'utilisation d'un tel composé pour la préparation d'un médicament destiné à traiter, une maladie génétique résultant d'au moins une mutation entraînant l'apparition d'un codon de terminaison précoce.
PCT/EP2008/052025 2007-02-19 2008-02-19 Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant Ceased WO2008101935A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2677877A CA2677877C (fr) 2007-02-19 2008-02-19 Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
JP2009549836A JP5544170B2 (ja) 2007-02-19 2008-02-19 新規インドール誘導化合物およびそれを含有する薬剤組成物
US12/527,071 US8895726B2 (en) 2007-02-19 2008-02-19 Compounds derived from indole and pharmaceutical compositions containing them
ES08716957.9T ES2569478T3 (es) 2007-02-19 2008-02-19 Nuevos compuestos derivados de indol y composiciones farmacéuticas que los contienen
CN2008800053707A CN101652364B (zh) 2007-02-19 2008-02-19 吲哚衍生化合物以及包含它们的药物组合物
EP08716957.9A EP2121685B1 (fr) 2007-02-19 2008-02-19 Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0753349A FR2912745A1 (fr) 2007-02-19 2007-02-19 Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
FR0753349 2007-02-19
FR0753975A FR2912746B1 (fr) 2007-02-19 2007-03-21 Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
FR0753975 2007-03-21

Publications (2)

Publication Number Publication Date
WO2008101935A2 WO2008101935A2 (fr) 2008-08-28
WO2008101935A3 true WO2008101935A3 (fr) 2009-01-22

Family

ID=38423082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/052025 Ceased WO2008101935A2 (fr) 2007-02-19 2008-02-19 Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant

Country Status (8)

Country Link
US (1) US8895726B2 (fr)
EP (1) EP2121685B1 (fr)
JP (1) JP5544170B2 (fr)
CN (1) CN101652364B (fr)
CA (1) CA2677877C (fr)
ES (1) ES2569478T3 (fr)
FR (2) FR2912745A1 (fr)
WO (1) WO2008101935A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2010143169A2 (fr) * 2009-06-12 2010-12-16 Société Splicos Composés s'utilisant dans le traitement du sida
EP2266972A1 (fr) * 2009-06-12 2010-12-29 Splicos Nouvelles molécules chimiques qui inhibent le mécanisme d'épissage pour le traitement de maladies résultant d'anomalies d'épissage
CN103189060A (zh) 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物
EP2465502A1 (fr) 2010-12-15 2012-06-20 Société Splicos Composés utiles pour traiter le SIDA
CN103562218B (zh) * 2011-03-24 2015-09-09 国家健康与医学研究院 显性负性hsp110突变体及其在预测和治疗癌症中的用途
CN102960745A (zh) * 2012-08-16 2013-03-13 熊智惠 果蔬兔肉干的制作方法
WO2014055644A2 (fr) 2012-10-02 2014-04-10 New York University Compositions pharmaceutique et traitement de maladies génétiques associées à une désintégration d'arn à médiation non-sens
EP2757161A1 (fr) 2013-01-17 2014-07-23 Splicos miRNA-124 comme biomarqueur de l'infection virale
MX382692B (es) 2013-07-05 2025-03-13 Abivax Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus.
EP2974729A1 (fr) 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
JP7304697B2 (ja) 2015-12-23 2023-07-07 ムーンショット ファーマ エルエルシー 未成熟終止コドンのリードスルーを促進することにより免疫反応を誘発するための方法
WO2018237326A1 (fr) 2017-06-22 2018-12-27 1AlMOONSHOT PHARMA LLC Méthodes de traitement du cancer au moyen de compositions comprenant de l'amlexanox et des immunomodulateurs
EP3669873A1 (fr) 2018-12-20 2020-06-24 Abivax Dérivés de quinoline destinés à être utilisés dans le traitement de maladies inflammatoires

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023255A2 (fr) * 2003-09-04 2005-03-17 Centre National De La Recherche Scientifique (Cnrs) Derives d’indole pour le traitement de maladies liees au processus d’epissage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149150C (fr) * 1992-11-27 2000-08-01 David R. Carver Composition injectable de taxol plus stable
EP1525185A1 (fr) * 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Composes d'acide acetylamino benzoique et leur utilisation pour la suppression de non-sens et le traitement de maladie
US7247741B2 (en) * 2005-01-21 2007-07-24 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023255A2 (fr) * 2003-09-04 2005-03-17 Centre National De La Recherche Scientifique (Cnrs) Derives d’indole pour le traitement de maladies liees au processus d’epissage

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BUU-HOI N P ET AL: "CARCINOGENIC NITROGEN COMPOUNDS. PART LVI. BENZCACRIDINES AND BENZOÅCARBAZOLES METHYLATED ON THE K-ZONE", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LONDON, GB, 1967, pages 662 - 665, XP001007988, ISSN: 0368-1769 *
CARVALHO, A. C. M. ET AL: "Investigation of geometry and some electronic properties of aza analogues of the ellipticine and olivacine derivatives", THEOCHEM , 539, 273-278 CODEN: THEODJ; ISSN: 0166-1280, 2001, XP002448770 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHENKMANM, RONNI L. ET AL: "Structure-activity relationships of mammalian topoisomerase II inhibitors related to ellipticine", XP002449138, retrieved from STN Database accession no. 1993:32514 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VERNON, JOHN M. ET AL: "Naphthalen-1,4-imine derivatives with bridgehead substituents", XP002449139, retrieved from STN Database accession no. 1977:484708 *
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (9), 1084-7 CODEN: JCPRB4; ISSN: 0300-922X, 1977 *
KANSAL V K ET AL: "THE BIOGENETIC SYNTHETIC AND BIOCHEMICAL ASPECTS OF ELLIPTICINE AN ANTITUMOR ALKALOID", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 42, no. 9, 1986, pages 2389 - 2408, XP002293633, ISSN: 0040-4020 *
MEDICINAL CHEMISTRY RESEARCH , 2(3), 165-72 CODEN: MCREEB; ISSN: 1054-2523, 1992 *
MILLER, R. BRYAN ET AL: "A general synthesis of 6H-pyrido[4,3-b]carbazole alkaloids", TETRAHEDRON LETTERS , 21(35), 3319-22 CODEN: TELEAY; ISSN: 0040-4039, 1980, XP002449134 *
MILLER, R. BRYAN ET AL: "Total synthesis of ellipticine and 9-methoxyellipticine via benzotriazole intermediates", JOURNAL OF ORGANIC CHEMISTRY , 48(6), 886-8 CODEN: JOCEAH; ISSN: 0022-3263, 1983, XP002449133 *
OHASHI M ET AL: "ELLIPTICINE AND RELATED ANTICANCER AGENTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 6, no. 12, 1996, pages 1285 - 1294, XP008034013, ISSN: 1354-3776 *
RIVALLE, C. ET AL: "11H-Pyrido[3',2':4,5]pyrrolo[2,3-g]isoquinolines (7-azaellipticines) substituted at position 6", TETRAHEDRON , 37(11), 2097-103 CODEN: TETRAB; ISSN: 0040-4020, 1981, XP002448771 *
TERUHISA TSUCHIMOTO & CO: "Easy access to aryl- and heteroaryl- annulated[a]carbazoles by the indium-catalyzed reaction of 2-arylindoles with propargyl ethers", ANGEW.CHEM. INT. ED., vol. 44, 2005, pages 1336 - 1340, XP002448772 *
VENDOME, JEREMIE ET AL: "Molecular Modeling of Wild-Type and D816V c-Kit Inhibition Based on ATP-Competitive Binding of Ellipticine Derivatives to Tyrosine Kinases", JOURNAL OF MEDICINAL CHEMISTRY , 48(20), 6194-6201 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002448769 *
WOLTHUIS, ENNO ET AL: "Reactions of benzyne with pyrroles", JOURNAL OF ORGANIC CHEMISTRY , 30(1), 190-3 CODEN: JOCEAH; ISSN: 0022-3263, 1965, XP002449135 *

Also Published As

Publication number Publication date
EP2121685B1 (fr) 2016-02-17
JP2010519214A (ja) 2010-06-03
FR2912746A1 (fr) 2008-08-22
CN101652364B (zh) 2013-09-18
CA2677877A1 (fr) 2008-08-28
CN101652364A (zh) 2010-02-17
ES2569478T3 (es) 2016-05-11
CA2677877C (fr) 2016-01-12
US8895726B2 (en) 2014-11-25
FR2912746B1 (fr) 2009-12-18
JP5544170B2 (ja) 2014-07-09
EP2121685A2 (fr) 2009-11-25
US20110003843A1 (en) 2011-01-06
FR2912745A1 (fr) 2008-08-22
WO2008101935A2 (fr) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
MX2009003802A (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta-2 adrenergico.
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
TW200833675A (en) Nicotinamide derivatives
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
AR064253A1 (es) Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MX2012006789A (es) Derivados de etinilo.
MX2011009700A (es) Derivado de amida.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
PH12013501928A1 (en) Pyrazolidin-3-one derivatives
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
WO2008092851A3 (fr) Compositions actives sur le plan pesticide comprenant des composés 3-acétyl-1-phénylpyrazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880005370.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2677877

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009549836

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008716957

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08716957

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12527071

Country of ref document: US